Program
Molecule
Potential Indications
Discovery
Lead Optimization
Preclinical Development
Phase 1a
Phase 1b/2
Late-Stage Development
SARM1 inhibition
SIR2501
CIPN, ALS & neurodegenerative diseases
NAMPT activation
SIR4156
Obesity, metabolic & neuromuscular diseases
RIPK1 inhibition
SIR9900
Inflammation & Immunological diseases, traumatic CNS conditions
Undisclosed
SIR8752
Inflammation & Immunological diseases
Undisclosed
SIR0811
Neurodegenerative diseases
Early-stage small-molecule programs
Undisclosed
Brain delivery platform 1* programs
Undisclosed
Undisclosed
Brain delivery platform 2
Undisclosed
Undisclosed
Program
SARM1 inhibition
Molecule
SIR2501
Potential Indications
CIPN, ALS & neurodegenerative diseases
Phase
Phase 1b/2
Program
NAMPT activation
Molecule
SIR4156
Potential Indications
Obesity, metabolic & neuromuscular diseases
Phase
Phase 1b/2
Program
RIPK1 inhibition
Molecule
SIR9900
Potential Indications
Inflammation & Immunological diseases, traumatic CNS conditions
Phase
Phase 1b/2
Program
Undisclosed
Molecule
SIR8752
Potential Indications
Inflammation & Immunological diseases
Phase
Phase 1a
Program
Undisclosed
Molecule
SIR0811
Potential Indications
Neurodegenerative diseases
Phase
Preclinical Development
Program
Early-stage small-molecule programs
Molecule
Potential Indications
Undisclosed
Phase
Discovery
Program
Brain delivery platform 1* programs
Molecule
Undisclosed
Potential Indications
Undisclosed
Phase
Discovery
Program
Brain delivery platform 2
Molecule
Undisclosed
Potential Indications
Undisclosed
Phase
Discovery
Targeting
Contributors of aging, degeneration,
metabolic dysfunction, and inflammation
Sironax Advances Enrollment in Phase 2 FORGE-LM Obesity Trial of NAMPT Activator SIR4156
WALTHAM, Mass., Oct. 13, 2026 – Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunologic, metabolic, and rare diseases, today announced it has achieved...